14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AVDL vs BHC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Bausch Health Companies Inc (BHC) on higher Unified Composite conviction (62.9/100 BUY vs. 44.1/100 HOLD) after splitting the core matrix 6–4 (led by Profitability & Quality), while BHC wins 5–1 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus BHC at $8.22 (1.9x Forward P/E, 27.2% operating margin).
Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. BHC 44.1/100 HOLD) and 0.14β · 2% Vol risk profile, whereas BHC leads top-line expansion (+9.7% YoY revenue growth, 0.01x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs BHC. Trailing 12-month operating profitability (AVDL 2.5% vs BHC 27.2%) and valuation multiples (AVDL 28.8x vs BHC 1.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
BHC Moat ProfileScale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $3.2B market capitalization and 27.2% operating margin.
OpEx & R&D Reinvestment45.4% of Rev ($5.05B)
90D Engineering Disclosures0 Published
Investor FAQ AVDL vs BHC Key Questions & Quantitative Answers
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Bausch Health Companies Inc (BHC) on higher Unified Composite conviction (62.9/100 BUY vs. 44.1/100 HOLD) after splitting the core matrix 6–4 (led by Profitability & Quality), while BHC wins 5–1 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus BHC at $8.22 (1.9x Forward P/E, 27.2% operating margin). Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. BHC 44.1/100 HOLD) and 0.14β · 2% Vol risk profile, whereas BHC leads top-line expansion (+9.7% YoY revenue growth, 0.01x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
BHC leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with BHC at +9.7% YoY revenue growth and +139.6% YoY earnings growth on $11.1B TTM revenue (72.6% gross margin, 27.2% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $11.1B for BHC. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus 45.4% of Rev ($5.05B) (0 disclosures) for BHC.
BHC screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas BHC trades at 1.9x Forward P/E, 2.0x Trailing P/E, 0.01x PEG, and 0.3x EV/Revenue (16.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus BHC (-11040.0% ROE) capital efficiency.
In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, BHC carries 471.5% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.96β · 111% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.